2009
DOI: 10.1590/s0100-736x2009000400008 View full text |Buy / Rent full text
|
|

Abstract: A distrofia muscular de Duchenne (DMD) é uma alteração neuromuscular caracterizada por contínua necrose muscular e degeneração, com eventual fibrose e infiltração por tecido adiposo. O aumento progressivo da fibrose intersticial no músculo impede a migração das células miogênicas, necessárias para a formação muscular. O modelo canino constitui-se nas melhores fenocópias da doença em humanos, quando comparados com outros modelos animais com distrofia. O tratamento antifibrose de pacientes DMD, tendo como alvo o… Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
2
1
1
0
3
0
2

Year Published

2010
2010
2017
2017

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

0
3
0
2
Order By: Relevance
“…In DMD patients, losartan potassium is used as an anti-fibrosis treatment because of its inhibition of TGF-beta due to the fact that it is an angiotensin inhibitor, and DMD patients may often present with increased levels of potassium, urea and creatinine. However, the use of losartan potassium in DGR administered orally at a dose of 50mg for nine weeks did not influence renal function, serum potassium level or blood pressure (SILVA et al, 2009).…”
Section: Advances In Dmd Therapy Using Grmdmentioning
See 1 more Smart Citation
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 7 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…In DMD patients, losartan potassium is used as an anti-fibrosis treatment because of its inhibition of TGF-beta due to the fact that it is an angiotensin inhibitor, and DMD patients may often present with increased levels of potassium, urea and creatinine. However, the use of losartan potassium in DGR administered orally at a dose of 50mg for nine weeks did not influence renal function, serum potassium level or blood pressure (SILVA et al, 2009).…”
Section: Advances In Dmd Therapy Using Grmdmentioning
“…GRDM dogs have been extensively studied and have led to a better understanding of the condition for research on DMD in humans, especially in the experimental evaluation of new treatments in preclinical trials (COLLINS & MORGAN, 2003;SHELTON & ENGVALL, 2005;BANKS & CHAMBERLAIN, 2008;SILVA et al, 2009;NAKAMURA & TAKEDA, 2011). Both DMD and DGR present progressive clinical signs and severe myopathy with initial fiber necrosis and regeneration associated with connective tissue proliferation in the endomysium and perimysium (VALENTINE et al, 1990,;MIJAZATO et al, 2011b;KORNEGAY et al, 2012).…”
Section: Dog As Model Of Muscular Dystrophymentioning
“…É de caráter recessivo e causada pela ausência ou disfunção da distrofina, proteína encontrada numa variedade de tecidos, principalmente nas musculaturas esquelética e cardíaca, nervos e regiões específicas do sistema nervoso central (Ambrosio et al 2009, Silva et al 2009). Clinicamente, caracteriza-se por grave alteração na musculatura esquelética, resultando em morte precoce do indivíduo acometido (Anderson et al 2002, Childers et al 2002, Hainsey et al 2003.…”
Section: Introductionunclassified
“…Originally, losartan, an ANG II type-1 (AT 1 )-receptor antagonist was used for the treatment of hypertension, and has been recently studied for its varied effects in different animal models (Hashimoto et al 1999, Suzuki et al 2001, Kumari et al 2004, Silva et al, 2009.…”
Section: Introductionmentioning